GlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017
The research demonstrated that:
- In cell culture, GMI-1271 and, to a greater extent GMI-1359, reduced multiple myeloma cell adhesion to stromal cells and inhibited chemotaxis of multiple myeloma cells toward conditioned media.
- The presence of GMI-1271 or GMI-1359 reduced stroma-induced drug resistance of multiple myeloma cells to carfilzomib and lenalidomide. In a preclinical model of multiple myeloma, combination therapy of GMI-1271 and lenalidomide profoundly delayed tumor growth.
- Combination therapy of carfilzomib with GMI-1271 or GMI-1359 prolonged survival of mice with multiple myeloma over treatment with carfilzomib alone.
"Our results show a strong effect on cancer cells in combination with
chemotherapy and importantly, are supportive of our ongoing Phase 1
clinical studies in multiple myeloma of GMI-1271 as well as our study of
GMI-1359 in multiple cancers," said
Details of the AACR presentation include:
Abstract #5005—Muz, B.B., et al. "Inhibition of E-Selectin or
E-selectin together with CXCR4 re-sensitizes multiple myeloma to
The AACR Annual Meeting 2017 takes place from
GMI-1271 is currently being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia (AML) and in a Phase 1 clinical trial in multiple myeloma. GMI-1359 is now in a Phase 1 clinical trial.
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease.
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidates, GMI-1271 and GMI-1359. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including the availability and timing of data from ongoing clinical
trials, the uncertainties inherent in the initiation of future clinical
trials, whether interim results from a clinical trial will be predictive
of the final results of the trial or results of early clinical trials
will be indicative of the results of future trials, expectations for
regulatory approvals, availability of funding sufficient for
GlycoMimetics' foreseeable and unforeseeable operating expenses and
capital expenditure requirements, other matters that could affect the
availability or commercial potential of GlycoMimetics' drug candidates
and other factors discussed in the "Risk Factors" section of
GlycoMimetics' Annual Report on Form 10-K that was filed with the
News Provided by Acquire Media